dm 4

DM4 (Ravtansine)可用于制备抗体药物偶联物，是抗微管蛋白剂。 它抑制细胞分裂。

DM4-SMe is a cytotoxic part of antibody-drug conjugates (ADCs) and a metabolite of antibody-maytansin conjugates (AMCs) and tubulin inhibitors, which can also be stabilized by disulfide bonds or thioether The bond binds to the antibody. The IC50 of DM4-SM

Maytansinoid DM4, a thiol-containing maytansine derivative, is a highly potent cytotoxic moiety utilized in ADC applications.

DM4-SMCC, a non-cleavable drug-linker conjugate for antibody-drug conjugates (ADC), leverages the antitumor efficacy of DM4 (an antitubulin agent) through attachment with the SMCC linker, exhibiting antitumor activity[1].

DM4-SPDP, a drug-linker conjugate, integrates the antitubulin agent DM4 with the linker SMCC, facilitating the creation of antibody drug conjugates[1]. Additionally, SPDP serves as a short-chain crosslinker enabling amine-to-sulfhydryl conjugation, leveraging NHS-ester and pyridyldithiol groups to establish cleavable (reducible) disulfide bonds with cysteine sulfhydryls[2][3].

SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugate (ADC) applications, employing the maytansine-based payload DM4 (a tubulin inhibitor) connected through a SPDB linker. This compound demonstrates significant anti-tumor efficacy.

DBA-DM4 is a drug-linker conjugate for antibody-drug conjugate (ADC) synthesis, combining the tubulin inhibitor DM1 with the SPDP linker[1].

Sulfo-SPDB-DM4 is a drug-linker conjugate designed for antibody-drug conjugates (ADCs) that employs the maytansine-based payload (DM4, an antitubulin agent) connected through the sulfo-SPDB linker.

Lys-Nε-SPDB-DM4 is a drug-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody drug conjugate (ADC).

DM4 (GMP)是 DM4 的 GMP 级别试剂。DM4 是一种用于制备抗体药物偶联物，是抗微管蛋白剂。 它抑制细胞分裂。

S-Me-DM4是DM4在胞内酶作用下发生S-甲基化反应形成的代谢产物。DM4本身是一种具有强细胞毒性的含硫醇类微管解聚剂，并可作为ADC Cytotoxin分子应用。

DM4-d6是DM4的一个氘代物,主要用于抗体活性分子偶联物的制备.作为一种抗微管蛋白剂,DM4 功能于抑制细胞分裂过程.

Mirvetuximab-DM4 (M9346A-DM4) 是一种靶向 FOLR1 的化合物，具有潜在的抗癌活性，可用于合成 Mirvetuximab soravtansine 和研究卵巢癌。

Sulfo-PDBA-DM4 is a drug-linker conjugate for antibody-drug conjugate (ADC) applications, combining the potent tubulin inhibitor DM4 with the gluthatione-cleavable linker Sulfo-PDBA. This configuration harnesses DM4's cytotoxic potential through Sulfo-PDBA's targeted delivery mechanism.

Tusamitamab ravtansine (SAR-408701) 是一款针对CEACAM5的人源化单克隆抗体与DM4细胞毒性药物经活性分子连接而成的抗体-药物偶联物(ADC)，专门靶向CEACAM5表达的肿瘤细胞。

Indatuximab ravtansine (BT-062) 作为一种抗体-药物偶联物 (ADC) (Antibody-Drug Conjugates (ADCs))，利用了 B-B4 的鼠 人嵌合形式并针对 CD138 显示出明确特异性，其与美登素类药物 DM4 通过二硫键耦合。此外，Indatuximab ravtansine 显示出显著的抗肿瘤活性。

DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for the development of antibody drug conjugates (ADCs).

DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid.

Mal-PEG4-VC-PAB-DMEA-duocarmycin-DM 是一种硫醇反应型 Drug-linker,Duocarmycin DM 是一种 DNA 小沟烷基化剂，可作为 ADC 结合物毒素，用于抗体-药物偶联物（ADC）的合成。

DBCO-PEG4-VC-PAB-Ahx-DM1 是一种是一种点击反应型 Drug-linker，含有 DBCO 基团，可以和含有 Azide 基团的分子发生环张力 (strain) 促进的炔-叠氮环加成反应 (SPAAC)，DM1 是一种微管蛋白抑制剂，DBCO-PEG4-VC-PAB-Ahx-DM1 可用于抗体-药物偶联物（ADC）的合成。

MA-PEG4-vc-PAB-DMEA-duocarmycin DM 是一种ADC药物连接物缀合物，由抗癌抗生素Duocarmycin DM 和 MA-PEG4-vc-PAB-DMEA连接而成。

KDM4-IN-4 是一种选择性组蛋白赖氨去甲基化酶 4 (KDM4)抑制剂，具有抗癌活性，抑制 KDM4A-Tudor 结构域，抑制细胞内 H3K4Me3 与 Tudor 结构域的结合。KDM4-IN-4 可用于研究癌症、肥胖症和心血管疾病。

Zavondemstat (QC8222 free base) 是一种组蛋白赖氨酸去甲基化酶4 (KDM4) 抑制剂，具有抗癌抗肿瘤活性，可用于研究三阴癌和乳腺癌。

KDM4-IN-2 is a potent and selective KDM4 KDM5 dual inhibitor with Kis of 4 and 7 nM for KDM4A and KDM5B, respectively.